companiesCompany
CStone Pharmaceuticals
CStone is a Chinese biotech whose PD-L1 antibody sugemalimab (Cejemly) was authorised in the EU in 2024 for first-line metastatic non-small cell lung cancer with chemotherapy.
Overview
CStone developed sugemalimab, approved by the NMPA in 2021 and by the European Commission in July 2024 for first-line metastatic NSCLC without EGFR, ALK, ROS1 or RET alterations in combination with platinum chemotherapy (GEMSTONE-302), and pralsetinib and ivosidenib rights in Greater China.
Headquarters
Suzhou, CN
Scorecard
All companies#127of 680 companies, score 19
- approved products +6
- targets +2
- modalities +2
- regions +2
- registry trials +7
1 approved, 0 in phase 3, 0 earlier, 1 targets, 11 registry studies. Formula on the scorecards page.
Type
biotech · 2616.HK
Stage
Public
Website